Latest News & Features
Americas
Pair of generic drug makers challenged validity of patent on priority, novelty and inventive step | EPO found the patent did not introduce any new matter not originally disclosed in the pharma company’s application. 19 December 2024
Americas
The act’s one-sided provisions and its disproportionate remedies cannot pass constitutional muster, argues John Cox of Barnes & Thornburg. 19 December 2024
Americas
LSIPR’s key event series to host its inaugural ceremony next year in Boston | Spotlight on top innovators and firms in life sciences IP | Gala to honour contributions across 21 categories with 15 judges. 17 December 2024
Americas
Regeneron inks deal over suit concerning a protein for testing COVID-19 treatments | BioNTech aims to resolve university dispute over patented tech used in the Comirnaty vaccine. 17 December 2024
Americas
A Delaware jury unanimously sided with Sanofi-owned biotech Inhibrx, clearing it of trade secrets misappropriation claims. Amy Candido of Wilson Sonsini shares insights into the defence strategy that led to the win. 16 December 2024
Americas
Firm expands its Mechanical & Electromechanical Technologies Practice with latest addition | Partner brings nearly two decades of experience in IP strategy, litigation, and transactions | Experience in biotechnology, medical devices, and blockchain. 12 December 2024
Europe
Paris Local Division revokes Dexcom patent and dismisses infringement action against rival | UPC revoked two other patents belonging to medical device company earlier in 2024. 12 December 2024
Americas
With 27 witnesses, plus both patent infringement and misappropriation claims, lead counsel for Insulet Alexandra Valenti and Scott Bluni share ‘a milestone’ in DTSA case law. 12 December 2024
Americas
BlueAllele “plausibly alleged” that some of Intellia’s uses of technology were not reasonably related to FDA approval | Biotech claimed competitor received over $100m from Regeneron for using innovation to research therapeutic candidates. 10 December 2024
Americas
Corporate legal teams can embrace the AI revolution by encouraging experimentation and managing risks proactively, according to a recent panel featuring leading pharma counsel. 10 December 2024